Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury

• Sponsor: University of Arizona (Other)
• Overall Status: Completed
• CT.gov ID: NCT02374918
• Collaborator: U.S. Army Medical Research Acquisition Activity (U.S. Fed)
• Enrollment: 77
• Location: 1
• Arms: 4
• Actual Duration (Months): 60
• Patients Per Site Per Month: 1.3

Study Details

Study Description

Brief Summary

The purpose of the research study is to understand the effectiveness of a six-week course of light exposure on cognitive functioning, mood, activity, and sleep in people that have suffered a head injury leading to a concussion.

Condition or Disease	Intervention/Treatment	Phase
Concussion, Mild; Post-Concussion Symptoms; Sleep Problems	Device: mTBI wavelength-1 bright light; Device: mTBI wavelength-2 bright light; Device: HC wavelength-1 bright light; Device: HC wavelength-2 bright light	N/A

Detailed Description

Mild traumatic brain injuries (mTBI) or "concussions" are an increasingly prevalent injury in the investigators society. Patients with post-concussion syndrome have been shown to have deficits on tests of short term memory, divided attention, multi-tasking, information processing speed, and reaction time, as well as alteration in mood and emotional functioning. Many patients have other vague complaints including fatigue, dizziness, irritability, sleep disturbances, and chronic headaches. Furthermore, sleep disruption of one of the most common complaints in patients suffering from traumatic brain injuries, with as many as 40 to 65% of patients with mTBI complaining of insomnia. Sleep problems in these patients are associated with poorer outcome, while resolution of the sleep disturbance is associated with improvement in cognitive functioning.

Despite recent evidence of the correlation between sleep quality and recovery from traumatic brain injury, and the well-established role of sleep in neural plasticity and neurogenesis, there have been virtually no direct studies of the causal effects of sleep on recovery following mTBI. However, it is quite likely that sleep plays a critical role in recovery following brain injury.

A particularly promising non-pharmacologic approach that shows potential in improving/modifying abnormalities of the circadian rhythm and sleep-wake schedule is bright light therapy. For the proposed investigation, the investigators hypothesize that bright light therapy may be helpful in improving the sleep of patients with a recent history of mTBI and may also have other mood elevating effects, both of which should promote positive treatment outcome in these individuals. Bright light therapy may increase the likelihood that they will recover more quickly, benefit more extensively from other forms of therapy, and build emotional and cognitive resilience.

This study will also have a healthy control (HC)/effect localization arm that will assist in identifying and mapping the brain systems before and after light exposure so that researchers may develop further insights into the relationship between concussion, light exposure, sleep, and brain function. This healthy control arm will also provide brain targets for study in the analysis of the Main Study Arm.

Study Design

• Study Type: Interventional
• Actual Enrollment: 77 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury
• Actual Study Start Date: Dec 1, 2014
• Actual Primary Completion Date: Sep 1, 2019
• Actual Study Completion Date: Dec 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: mTBI wavelength-1 bright light 30 minutes daily light exposure for 6 weeks	Device: mTBI wavelength-1 bright light; 6 weeks of daily light exposure, 30 minutes per morning
Placebo Comparator: mTBI wavelength-2 bright light 30 minutes daily light exposure for 6 weeks	Device: mTBI wavelength-2 bright light; 6 weeks of daily light exposure, 30 minutes per morning
Experimental: HC wavelength-1 bright light 30 minutes of light exposure	Device: HC wavelength-1 bright light; 30 minutes of light exposure
Placebo Comparator: HC wavelength-2 bright light 30 minutes of light exposure	Device: HC wavelength-2 bright light; 30 minutes of light exposure

Outcome Measures

Primary Outcome Measures

1. Sleep Quality - Pittsburgh Sleep Quality Index (PSQI) [Post 6-week intervention]

   The Pittsburgh Sleep Quality Index (PSQI) subscale measurement that was used is overall sleep quality, which is derived from question 6 on the assessment and uses a Likert scale of 0 to 3. A score of 0 represents "very good" sleep quality (better outcome), while a measurement of 3 represents "very bad" sleep quality (worse outcome).

2. Sleep Quality - Actigraphy Sleep Efficiency [Post 6-week intervention]

   Sleep Efficiency is the overall percentage of time that the participant was scored as sleeping during their night of sleep (range: 0-100%). Higher percentages suggest higher sleep quality and a better outcome.

3. Sleep Quality - Actigraphy Wake After Sleep Onset [Post 6-week intervention]

   Wake After Sleep Onset (WASO) is how many minutes the participant, during their night of sleep, was determined to be awake after their sleep onset. Sleep onset is defined as a state of at least 2 minutes of uninterrupted sleep. Higher values indicate a worse outcome (range: 1-125 minutes).

4. Executive Function Task - Multi-Source Interference Task (MSIT) [Post 6-week intervention]

   Neural activation during functional magnetic resonance imaging (fMRI) measuring executive functioning using the MSIT.

5. Performance on Neuropsychological Assessment - Automated Neuropsychological Assessment Metrics [Post 6-week intervention]

   The Automated Neuropsychological Assessment Metrics (ANAM) is a neuropsychological battery that uses individual tests to measure cognitive efficiency in areas including attention, concentration, reaction time, memory, processing speed, and decision making. Subscale scores are put in terms of a throughput score, which is calculated to be a ratio of correct responses per minute, as a way to measure cognitive efficiency in the participant; as such, the units for the throughput scores would be in terms of correct responses/minute. Higher throughput scores indicate increased levels of cognitive efficiency in the relevant subscale. The throughput score ranges for the ANAM subscales are: code substitution learning: 0-147 responses per minute procedural reaction time: 0-151 responses per minute mathematical processing: 0-145 responses per minute matching to sample: 0-97 responses per minute code substitution delayed: 0-155 responses per minute

6. Performance on Neuropsychological Assessment - Repeatable Battery for the Assessment of Neuropsychological Status [Post 6-week intervention]

   The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) uses all of its subscales to calculate the RBANS total score (index). To obtain the RBANS total score (index), the raw scores of the subtests must first be computed into index scores for their relevant subscale (different subtest raw scores feed into specific subscales) using RBANS specific tables that have scaled scores embedded and are normed for the age of the participant. The index scores of each subscale are then summed together to get the Sum of Index Scores, which has a possible range of 200-800. Once the Sum of Index Scores is found, the total score (index) is then found using another RBANS specific table with scaled scores embedded within it. The total score (index) has a possible range of 40-160, with a higher total score (index) is related to a better outcome.

7. Performance on Neuropsychological Assessment - Psychomotor Vigilance Task [Post 6-week intervention]

   The Psychomotor Vigilance Task (PVT) is a task that tests alertness by having the participant press a button every time they see a stimulus image appear on a screen. This image is presented at random 2-10 second intervals throughout the entirety of the task. The reaction time (RT) is one of the PVT measurements and is the time, measured in milliseconds, that it takes for the participant to view the stimulus image and then press the button, confirming that they have indeed viewed the stimulus image at that time. The PVT measures speed using the following equation: 1/RT * 1000. The PVT measurement used here is average speed, so all the calculated speeds were then averaged over the entire trial period to obtain the final value for that trial at that time point (post-tx 1,2,3). Since the PVT is a timed measurement of reaction times, lower scores are considered 'better' or indicate an increased level of vigilance.

8. Daytime Sleepiness - Epworth Sleepiness Scale [Post 6-week intervention]

   The Epworth Sleepiness Scale (ESS) is an 8-item questionnaire that characterizes the likelihood of the participant 'dozing off' during typical daily activities over their last 2 weeks, and uses a 0-3 point Likert scale, where 0 corresponds to "Would never doze" and 3 corresponds to having a "High chance of dozing" during the activity in question. The ESS score is calculated by adding up all the scores for each question, which means that the ESS score has a range of 0-24, while a higher score indicates that the participant had more issues with daytime sleepiness (worse outcome).

9. Daytime Sleepiness - Functional Outcome of Sleep Questionnaire [Post 6-week intervention]

   The Functional Outcome of Sleep Questionnaire (FOSQ) questions 1-26 use a 1-4 (ordinal) likert (1 = "No difficulty" with sleepiness, 4 = "Yes, extreme difficulty" with sleepiness) and the participant also has the option of putting 0 = "I don't do this activity for other reasons". FOSQ questions 27-30 use a 1-4 Likert scale where 1 = "Very low" in terms of characterizing the level that sleepiness affects different aspects of their intimate romantic relations, while a 4 = "High" amount of impact on their intimate romantic relations. The FOSQ total score measurement is determined by calculating the mean of all 5 subscale scores and then multiplying that value by 5 (range: 0-24). A higher score indicates that the participant had more issues with daytime sleepiness.

10. Post-Concussive Symptoms (Rivermead Post-Concussion Symptoms Questionnaire) [Post 6-week intervention]

    The Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ) will be used to assess post-concussive symptoms related to sleep. All questions on the RPCSQ use a 0 to 4 Likert scale concerning the severity of experiencing differing symptoms, where 0 = "not experienced" and 4 = "severe problem". As such, having a higher score is indicative that the participant is having more serious sleep issues related to their head injury. The RPCSQ subscale measurements that were used below are: RPQ3, which is the summed scores from the first 3 questions on the form, with the subscale total ranging from 0-12, and RPQ13, which is the summed scores from questions 4 to 16 on the form, with the subscale total ranging from 0-52. The RPQ3 subscale is associated with earlier symptom clusters of post-concussive symptoms as they relate to sleep disturbances, while the RPQ13 subscale is associated with later symptom clusters of post-concussive symptoms as they relate to sleep disturbances.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 50 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion criteria:

• Age range between 18 and 50.

• The primary language of the subjects must be English.

• Subjects have experienced a "concussion" or mTBI within the preceding 18 months, but no sooner that 4 weeks prior to their screening. The occurrence of a concussion or mTBI must be documented by a medical report or other professional witness documentation.

• If documented, Glasgow Coma Scale in the range of 13-15 following the injury.

• Subjects must have complaints of sleep difficulties that emerged or worsened following the most recent head injury.

• At least half of subjects must have evidence of sleep onset insomnia or delayed sleep phase disorder.

Exclusion criteria:

• Any other history of neurological illness, current Diagnostic Statistical Manual (DSM-IV) Axis I disorder, lifetime history of psychotic disorder, or head injury with loss of consciousness > 30 minutes

• Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV, brain tumor, etc.)

• Abnormal visual acuity that is not corrected by contact lenses

• Metal within the body, claustrophobia, or other contraindications for neuroimaging

• Less than 9th grade education

• Excess current alcohol use (more than 2 instances of intake of 5+ drinks (men) when or 4+ drinks (women) when drinking in the past two months, and/or on average drinking > 2 drinks per day (men); > 1 drinks per day (women) during the past two months

• History of alcoholism or substance use disorder

• Significant use of illicit drugs

• History of marijuana use within the past 6 weeks and/or use of marijuana before the age of 16.

Subjects who engage in shift-work, night work, or who have substantially desynchronized work-sleep schedules (i.e., sleeping later than 10:00 a.m. more than once a week) will be excluded.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Arizona	Tucson	Arizona	United States	85724

Sponsors and Collaborators

• University of Arizona
• U.S. Army Medical Research Acquisition Activity

Investigators

• Principal Investigator: William D Killgore, Ph.D., University of Arizona

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 9, 2018
• Informed Consent Form - Jul 17, 2018

More Information

Publications

None provided.

• Responsible Party: William D. Killgore, Principal Investigator, University of Arizona
• ClinicalTrials.gov Identifier: NCT02374918
• Other Study ID Numbers: 1404301151
• First Posted: Mar 2, 2015
• Last Update Posted: Jun 24, 2021
• Last Verified: Jun 1, 2021

• Keywords provided by William D. Killgore, Principal Investigator, University of Arizona: Mild traumatic brain injury; Concussion; Sleep problems; Brain imaging; fMRI
• Additional relevant MeSH terms: Brain Injuries; Brain Injuries, Traumatic; Brain Concussion; Dyssomnias; Parasomnias; Sleep Wake Disorders; Post-Concussion Syndrome

Study Results

Participant Flow

Recruitment Details	Participants were recruited from around the city of Tucson. The first participant was enrolled in December 2014. The Effect Localization Arm completed enrollment in April 2015 and the Treatment Arm completed enrollment in May 2019.
Pre-assignment Detail	No pre-assignment criteria were needed after enrollment but before study group assignment for the Effect Localization Arm. For the Treatment Arm, participants went through a screening visit before study group assignment and were excluded based on the inclusion/exclusion criteria.

Arm/Group Title	mTBI Wavelength-1 Bright Light	mTBI Wavelength-2 Bright Light	HC Wavelength-1 Bright Light	HC Wavelength-2 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes of light exposure HC wavelength-1 bright light: 30 minutes of light exposure	30 minutes of light exposure HC wavelength-2 bright light: 30 minutes of light exposure
Period Title: Overall Study
STARTED	17	18	22	20
COMPLETED	14	17	18	18
NOT COMPLETED	3	1	4	2

Baseline Characteristics

Arm/Group Title	mTBI Wavelength-1 Bright Light	mTBI Wavelength-2 Bright Light	HC Wavelength-1 Bright Light	HC Wavelength-2 Bright Light	Total
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes of light exposure HC wavelength-1 bright light: 30 minutes of light exposure	30 minutes of light exposure HC wavelength-2 bright light: 30 minutes of light exposure	Total of all reporting groups
Overall Participants	17	18	18	18	71
Age (Count of Participants)
<=18 years	3 17.6%	1 5.6%	1 5.6%	2 11.1%	7 9.9%
Between 18 and 65 years	14 82.4%	17 94.4%	17 94.4%	16 88.9%	64 90.1%
>=65 years	0 0%	0 0%	0 0%	0 0%	0 0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	25.53 (8.65)	26.23 (7.62)	21.61 (2.86)	22.28 (4.03)	23.95 (6.41)
Sex: Female, Male (Count of Participants)
Female	12 70.6%	10 55.6%	9 50%	10 55.6%	41 57.7%
Male	5 29.4%	8 44.4%	9 50%	8 44.4%	30 42.3%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	2 11.8%	3 16.7%	3 16.7%	6 33.3%	14 19.7%
Not Hispanic or Latino	15 88.2%	15 83.3%	15 83.3%	12 66.7%	57 80.3%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	1 5.9%	0 0%	1 5.6%	3 16.7%	5 7%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	1 5.6%	0 0%	0 0%	1 1.4%
White	16 94.1%	17 94.4%	15 83.3%	15 83.3%	63 88.7%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	2 11.1%	0 0%	2 2.8%
Region of Enrollment (participants) [Number]
United States	17 100%	18 100%	18 100%	18 100%	67 94.4%
Post-Concussive Symptoms - Rivermead Post-Concussion Symptoms Questionnaire (units on a scale) [Mean (Standard Deviation) ]
RPQ3	3.3 (3)	3.5 (2.5)	3.4 (2.7)
RPQ13	12.3 (13)	15.9 (8)	14.1 (10.9)
Sleep Quality - PSQI (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	1.44 (0.7)	1.76 (0.66)	1.60 (0.69)
Actigraphy - Sleep Efficiency (Percentage of time asleep) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Percentage of time asleep]	82.53 (4.83)	80.98 (4.71)	81.73 (4.63)
Actigraphy - Wake After Sleep Onset (WASO) (Minutes) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Minutes]	11.2 (3.02)	11.97 (3.23)	11.60 (3.06)
RBANS total score (index) (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	88.2 (10)	96.1 (11.5)	92.53 (11.4)
PVT average speed - Run 1 (responses/second) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [responses/second]	3.27 (0.41)	3.52 (0.35)	3.39 (0.39)
PVT average speed - Run 2 (responses/second) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [responses/second]	3.22 (0.51)	3.45 (0.42)	3.33 (0.48)
PVT average speed - Run 3 (responses/second) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [responses/second]	3.17 (0.43)	3.50 (0.59)	3.33 (0.53)
ANAM Code Substitution Learning - thruput score (correct responses/minute) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [correct responses/minute]	46.78 (14.74)	55.88 (12.39)	51.20 (13.79)
ANAM Procedural Reaction Time - thruput score (correct responses/minute) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [correct responses/minute]	86.83 (19.55)	97.06 (19.41)	95.26 (17.98)
ANAM Mathematical Processing - thruput score (correct responses/minute) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [correct responses/minute]	17.89 (8.44)	21.18 (7.38)	19.49 (7.89)
ANAM Matching to Sample - thruput score (correct responses/minute) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [correct responses/minute]	29.5 (8.05)	33.29 (11.55)	31.34 (9.86)
ANAM Code Substitution delay - thruput score (correct responses/minute) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [correct responses/minute]	41.06 (13.11)	52.88 (8.72)	46.8 (11.96)
ESS total score (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	8.72 (3.32)	8.18 (3.28)	8.46 (3.27)
FOSQ Total Score (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	17.10 (2.18)	15.37 (3.82)	14.06 (10.86)

Outcome Measures

1. Primary Outcome

Title	Sleep Quality - Pittsburgh Sleep Quality Index (PSQI)
Description	The Pittsburgh Sleep Quality Index (PSQI) subscale measurement that was used is overall sleep quality, which is derived from question 6 on the assessment and uses a Likert scale of 0 to 3. A score of 0 represents "very good" sleep quality (better outcome), while a measurement of 3 represents "very bad" sleep quality (worse outcome).
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

The PSQI was not administered to the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [score on a scale]	1.28 (.67)	1.35 (.7)

2. Primary Outcome

Title	Sleep Quality - Actigraphy Sleep Efficiency
Description	Sleep Efficiency is the overall percentage of time that the participant was scored as sleeping during their night of sleep (range: 0-100%). Higher percentages suggest higher sleep quality and a better outcome.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

Actigraphy data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [percentage of time asleep]	82.57 (4.2)	83.43 (5.11)

3. Primary Outcome

Title	Sleep Quality - Actigraphy Wake After Sleep Onset
Description	Wake After Sleep Onset (WASO) is how many minutes the participant, during their night of sleep, was determined to be awake after their sleep onset. Sleep onset is defined as a state of at least 2 minutes of uninterrupted sleep. Higher values indicate a worse outcome (range: 1-125 minutes).
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

Actigraphy data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [minutes]	11.66 (2.91)	10.4 (3.32)

4. Primary Outcome

Title	Executive Function Task - Multi-Source Interference Task (MSIT)
Description	Neural activation during functional magnetic resonance imaging (fMRI) measuring executive functioning using the MSIT.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

Data was collected for this measure but was unable to be analyzed due to issues extracting the data from the computer it was stored on. In addition, MSIT data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study 6-weeks after the inital visit.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	0	0

5. Primary Outcome

Title	Performance on Neuropsychological Assessment - Automated Neuropsychological Assessment Metrics
Description	The Automated Neuropsychological Assessment Metrics (ANAM) is a neuropsychological battery that uses individual tests to measure cognitive efficiency in areas including attention, concentration, reaction time, memory, processing speed, and decision making. Subscale scores are put in terms of a throughput score, which is calculated to be a ratio of correct responses per minute, as a way to measure cognitive efficiency in the participant; as such, the units for the throughput scores would be in terms of correct responses/minute. Higher throughput scores indicate increased levels of cognitive efficiency in the relevant subscale. The throughput score ranges for the ANAM subscales are: code substitution learning: 0-147 responses per minute procedural reaction time: 0-151 responses per minute mathematical processing: 0-145 responses per minute matching to sample: 0-97 responses per minute code substitution delayed: 0-155 responses per minute
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

ANAM data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
ANAM Code substitution learning -thruput score	51.3 (15.8)	60.3 (10.8)
ANAM Procedural Reaction Time - thruput score	89.8 (19.5)	101.3 (17.9)
ANAM Mathematical Processing - thruput score	18 (8.5)	22.1 (8.2)
ANAM Matching to Sample - thruput score	30.5 (10.1)	33 (12.2)
ANAM Code substitution delay-thruput score	43.3 (14.2)	56.2 (8.9)

6. Primary Outcome

Title	Performance on Neuropsychological Assessment - Repeatable Battery for the Assessment of Neuropsychological Status
Description	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) uses all of its subscales to calculate the RBANS total score (index). To obtain the RBANS total score (index), the raw scores of the subtests must first be computed into index scores for their relevant subscale (different subtest raw scores feed into specific subscales) using RBANS specific tables that have scaled scores embedded and are normed for the age of the participant. The index scores of each subscale are then summed together to get the Sum of Index Scores, which has a possible range of 200-800. Once the Sum of Index Scores is found, the total score (index) is then found using another RBANS specific table with scaled scores embedded within it. The total score (index) has a possible range of 40-160, with a higher total score (index) is related to a better outcome.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

RBANs data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [units on a scale]	88.5 (10.7)	97.6 (12.2)

7. Primary Outcome

Title	Performance on Neuropsychological Assessment - Psychomotor Vigilance Task
Description	The Psychomotor Vigilance Task (PVT) is a task that tests alertness by having the participant press a button every time they see a stimulus image appear on a screen. This image is presented at random 2-10 second intervals throughout the entirety of the task. The reaction time (RT) is one of the PVT measurements and is the time, measured in milliseconds, that it takes for the participant to view the stimulus image and then press the button, confirming that they have indeed viewed the stimulus image at that time. The PVT measures speed using the following equation: 1/RT * 1000. The PVT measurement used here is average speed, so all the calculated speeds were then averaged over the entire trial period to obtain the final value for that trial at that time point (post-tx 1,2,3). Since the PVT is a timed measurement of reaction times, lower scores are considered 'better' or indicate an increased level of vigilance.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

PVT data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study 6-weeks after the initial visit.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
PVT average speed - Run 1 - post-tx	3.3 (0.4)	3.4 (0.3)
PVT average speed - Run 2 - post-tx	3.3 (0.7)	3.4 (0.4)
PVT average speed - Run 3 - post-tx	3.3 (0.6)	3.4 (0.5)

8. Primary Outcome

Title	Daytime Sleepiness - Epworth Sleepiness Scale
Description	The Epworth Sleepiness Scale (ESS) is an 8-item questionnaire that characterizes the likelihood of the participant 'dozing off' during typical daily activities over their last 2 weeks, and uses a 0-3 point Likert scale, where 0 corresponds to "Would never doze" and 3 corresponds to having a "High chance of dozing" during the activity in question. The ESS score is calculated by adding up all the scores for each question, which means that the ESS score has a range of 0-24, while a higher score indicates that the participant had more issues with daytime sleepiness (worse outcome).
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

ESS data was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [units on a scale]	9.33 (3.74)	6.82 (3.11)

9. Primary Outcome

Title	Daytime Sleepiness - Functional Outcome of Sleep Questionnaire
Description	The Functional Outcome of Sleep Questionnaire (FOSQ) questions 1-26 use a 1-4 (ordinal) likert (1 = "No difficulty" with sleepiness, 4 = "Yes, extreme difficulty" with sleepiness) and the participant also has the option of putting 0 = "I don't do this activity for other reasons". FOSQ questions 27-30 use a 1-4 Likert scale where 1 = "Very low" in terms of characterizing the level that sleepiness affects different aspects of their intimate romantic relations, while a 4 = "High" amount of impact on their intimate romantic relations. The FOSQ total score measurement is determined by calculating the mean of all 5 subscale scores and then multiplying that value by 5 (range: 0-24). A higher score indicates that the participant had more issues with daytime sleepiness.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

FOSQ was not collected for the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
Mean (Standard Deviation) [units on a scale]	16.28 (1.88)	17.33 (2.39)

10. Primary Outcome

Title	Post-Concussive Symptoms (Rivermead Post-Concussion Symptoms Questionnaire)
Description	The Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ) will be used to assess post-concussive symptoms related to sleep. All questions on the RPCSQ use a 0 to 4 Likert scale concerning the severity of experiencing differing symptoms, where 0 = "not experienced" and 4 = "severe problem". As such, having a higher score is indicative that the participant is having more serious sleep issues related to their head injury. The RPCSQ subscale measurements that were used below are: RPQ3, which is the summed scores from the first 3 questions on the form, with the subscale total ranging from 0-12, and RPQ13, which is the summed scores from questions 4 to 16 on the form, with the subscale total ranging from 0-52. The RPQ3 subscale is associated with earlier symptom clusters of post-concussive symptoms as they relate to sleep disturbances, while the RPQ13 subscale is associated with later symptom clusters of post-concussive symptoms as they relate to sleep disturbances.
Time Frame	Post 6-week intervention

Outcome Measure Data

Analysis Population Description

The RPCSQ was not administered to the HC wavelength-2 and HC wavelength-1 arms of this study.

Arm/Group Title	mTBI Wavelength-2 Bright Light	mTBI Wavelength-1 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning
Measure Participants	18	17
RPQ3	3 (2.4)	2.7 (2.7)
RPQ13	12.8 (11.1)	11.1 (8.3)

Adverse Events

Time Frame	6 weeks
Arm/Group Title	mTBI Wavelength-1 Bright Light		mTBI Wavelength-2 Bright Light		HC Wavelength-1 Bright Light		HC Wavelength-2 Bright Light
Arm/Group Description	30 minutes daily light exposure for 6 weeks mTBI wavelength-1 bright light: 6 weeks of daily light exposure, 30 minutes per morning		30 minutes daily light exposure for 6 weeks mTBI wavelength-2 bright light: 6 weeks of daily light exposure, 30 minutes per morning		30 minutes of light exposure HC wavelength-1 bright light: 30 minutes of light exposure		30 minutes of light exposure HC wavelength-2 bright light: 30 minutes of light exposure
All Cause Mortality
	mTBI Wavelength-1 Bright Light		mTBI Wavelength-2 Bright Light		HC Wavelength-1 Bright Light		HC Wavelength-2 Bright Light
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/18 (0%)		0/22 (0%)		0/20 (0%)
Serious Adverse Events
	mTBI Wavelength-1 Bright Light		mTBI Wavelength-2 Bright Light		HC Wavelength-1 Bright Light		HC Wavelength-2 Bright Light
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/18 (0%)		0/22 (0%)		0/20 (0%)
Other (Not Including Serious) Adverse Events
	mTBI Wavelength-1 Bright Light		mTBI Wavelength-2 Bright Light		HC Wavelength-1 Bright Light		HC Wavelength-2 Bright Light
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/18 (0%)		0/22 (0%)		0/20 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.